The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α, PTH, PTHrP, and 1,25(OH)2D3.
Open accessAbstract
Osteoprotegerin (OPG) is a secreted protein that inhibits osteoclast formation and activity and appears to be a critical regulator of bone mass and metabolism. In the current study, mice were challenged with various cytokines and hormones (interleukin-1β, tumor necrosis factor-α, parathyroid hormone, parathyroid hormone-related protein, and 1α,25-dihydroxyvitamin D3) that are known to increase bone resorption and cause hypercalcemia and treated concurrently with either a recombinant chimeric Fc fusion form of human OPG, with enhanced biological activity (cOPG) (2.5 mg/kg/day) or vehicle. Mice receiving these bone-resorbing factors became hypercalcemic by day 3 after commencing treatment and had increased bone resorption as evidenced by elevated osteoclast numbers on day 5. Concurrent cOPG treatment prevented hypercalcemia (p < 0.05) and maintained osteoclast numbers in the normal range (p < 0.001). The demonstration that cOPG can inhibit bone resorption suggests that this molecule may be useful in the treatment of diseases including hyperparathyroidism, humoral hypercalcemia of malignancy, osteoporosis, and inflammatory bone disease, which are characterized, in part, by increases in osteoclastic bone resorption.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In support of the latter notion, OPG treatment of mice was able to fully prevent the proresorptive effects of IL-1 and TNF-␣ (21).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [21]
In the citing paper
“OPG prevents the ability of proresorptive agents (IL-1, TNF-␣, PTH, PTHrP, vitamin D) to increase bone resorption in mice (21), which is consistent with the interpretation that those agents increase bone resorption by increasing the RANKL:OPG ratio.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multiple Comparison Procedure for Comparing Several Treatments with a Control
Dunnett, C. W. (1955) · Journal of the American Statistical Association · doi:10.1080/01621459.1955.10501294 · Cited by 6,097
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Self-citationA homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201
Wong, B. R., Rho, J., Arron, J. R., Robinson, E. A., Orlinick, J. R., Chao, M. V., Kalachikov, S. M., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
An interleukin 1 like factor stimulates bone resorption in vitro
Gowen, M., Wood, D. D., Ihrie, E. J., McGuire, M. K. B., & Russell, R. G. G. (1983) · Nature · doi:10.1038/306378a0 · Cited by 1,012
Arend, W. P., & Dayer, J. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380202 · Cited by 891
Cited by
Sorted by citations
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670
Self-citationKobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.275 · Cited by 1,309
Li, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1566 · Cited by 1,119
Self-citationKearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
RANK-L and RANK: T Cells, Bone Loss, and Mammalian Evolution
Theill, L. E., Boyle, W. J., & Penninger, J. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064753 · Cited by 825
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 777
Self-citationRaphel, J., Holodniy, M., Goodman, S. B., & Heilshorn, S. C. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.016 · Cited by 678
Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586
Min, H., Morony, S., Sarosi, I., Dunstan, C. R., Capparelli, C., Scully, S., Van, G., Kaufman, S., Kostenuik, P. J., Lacey, D. L., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.463 · Cited by 550
Self-citationPearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., & Choi, Y. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201394498 · Cited by 518
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484
Self-citationBody, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., et al. (2003) · Cancer · doi:10.1002/cncr.11138 · Cited by 383
Self-citationOsteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.
Price, P. A., June, H. H., Buckley, J. R., & Williamson, M. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1001.097102 · Cited by 376
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Croucher, P. I. (2001) · Blood · doi:10.1182/blood.v98.13.3534 · Cited by 376
Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis
Romas, E., Sims, N. A., Hards, D. K., Lindsay, M., Quinn, J. W. M., Ryan, P. F. J., Dunstan, C. R., Martin, T. J., & Gillespie, M. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64417-3 · Cited by 368
Self-citationThe role of the immune system in the pathophysiology of osteoporosis
Clowes, J. A., Riggs, B. L., & Khosla, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00334.x · Cited by 366
Morony, S., Capparelli, C., Sarosi, I., Lacey, D. L., Dunstan, C. R., & Kostenuik, P. J. (2001) · PubMed · Cited by 289
Self-citationRedlich, K., Hayer, S., Maier, A., Dunstan, C. R., Tohidast‐Akrad, M., Lang, S., Türk, B., Pietschmann, P., Woloszczuk, W., Haralambous, S., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10097 · Cited by 285
Self-citationBiology of bone and how it orchestrates the form and function of the skeleton
Sommerfeldt, D. W., & Rubin, C. T. (2001) · European Spine Journal · doi:10.1007/s005860100283 · Cited by 293
Local communication on and within bone controls bone remodeling
Henriksen, K., Neutzsky-Wulff, A. V., Bonewald, L. F., & Karsdal, M. A. (2009) · Bone · doi:10.1016/j.bone.2009.03.671 · Cited by 292
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281
The OPG/RANKL/RANK system in metabolic bone diseases.
Hofbauer, L. C., Kühne, C. A., & Viereck, V. (2004) · PubMed · Cited by 254
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.
Standal, T., Seidel, C., Hjertner, Ø., Plesner, T., Sanderson, R. D., Waage, A., Borset, M., & Sundan, A. (2002) · Blood · doi:10.1182/blood-2002-04-1190 · Cited by 244
Magnesium Deficiency: Effect on Bone and Mineral Metabolism in the Mouse
Rude, R. K., Gruber, H. E., Wei, L. Y., Frausto, A., & Mills, B. G. (2003) · Calcified Tissue International · doi:10.1007/s00223-001-1091-1 · Cited by 242
IL-1 plays an important role in the bone metabolism under physiological conditions
Lee, Y.-M., Fujikado, N., Manaka, H., Yasuda, H., & Iwakura, Y. (2010) · International Immunology · doi:10.1093/intimm/dxq431 · Cited by 226
Role of RANKL and RANK in bone loss and arthritis
Jones, D. H., Kong, Y.-Y., & Penninger, J. M. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii32 · Cited by 225
Canon, J. R., Roudier, M. P., Bryant, R., Morony, S., Stolina, M., Kostenuik, P. J., & Dougall, W. C. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9127-1 · Cited by 209
Self-citationZiolkowska, M., Kurowska, M., Radzikowska, A., Luszczykiewicz, G., Wiland, P., Dziewczopolski, W., Filipowicz‐Sosnowska, A., Pazdur, J., Szechinski, J., Kowalczewski, J., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10388 · Cited by 200
Walsh, M. C., & Choi, Y. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00027-3 · Cited by 201
Bone loss: Factors that regulate osteoclast differentiation - an update
Roux, S., & Orcel, P. (2000) · Arthritis Research & Therapy · doi:10.1186/ar127 · Cited by 193
Osteoprotegerin diminishes advanced bone cancer pain.
Luger, N. M., Honoré, P., Sabino, M., Schwei, M. J., Rogers, S. D., Mach, D. B., Clohisy, D. R., & Mantyh, P. W. (2001) · PubMed · Cited by 195
Polymorphisms in the Osteoprotegerin Gene Are Associated With Osteoporotic Fractures
Langdahl, B. L., Carstens, M., Stenkjær, L. L., & Eriksen, E. F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1245 · Cited by 190
Demographic variations in the rising incidence of esophageal adenocarcinoma in white males
Bollschweiler, E., Wolfgarten, E., Gutschow, C. A., & H�lscher, A. H. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3 · Cited by 452
A potent analog of 1α,25-dihydroxyvitamin D 3 selectively induces bone formation
Shevde, N. K., Plum, L. A., Clagett‐Dame, M., Yamamoto, H., Pike, J. W., & DeLuca, H. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202471299 · Cited by 176
Kazama, J. J., Shigematsu, T., Yano, K., Tsuda, E., Miura, M., Iwasaki, Y., Kawaguchi, Y., Gejyo, F., Kurokawa, K., & Fukagawa, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.31402 · Cited by 169
Hofbauer, L. C., & Heufelder, A. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6702 · Cited by 178
Osteoprotegerin ligand: a regulator of immune responses and bone physiology
Kong, Y., Boyle, W. J., & Penninger, J. M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01718-7 · Cited by 161
Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett, G., Redlich, K., Hayer, S., Zwerina, J., Bolon, B., Dunstan, C., Görtz, B., Schulz, A., Bergmeister, H., Kollias, G., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11150 · Cited by 150
Self-citationCapparelli, C., Kostenuik, P. J., Morony, S., Starnes, C. O., Weimann, B., Van, G. Y., Scully, S. A., Qi, M., Lacey, D. L., & Dunstan, C. R. (2000) · PubMed · Cited by 147
Self-citationKondo, H., Guo, J., & Bringhurst, F. R. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.9.1667 · Cited by 143
Zou, W., Hakim, I., Tschoep, K., Endres, S., & Bar‐Shavit, Z. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1202 · Cited by 143
Kostenuik, P. J., Capparelli, C., Morony, S., Adamu, S., Shimamoto, G., Shen, V., Lacey, D. L., & Dunstan, C. R. (2001) · Endocrinology · doi:10.1210/endo.142.10.8437 · Cited by 140
Self-citationDai, S.-M., Nishioka, K., & Yudoh, K. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.018481 · Cited by 137
Redlich, K., Görtz, B., Hayer, S., Zwerina, J., Doerr, N., Kostenuik, P., Bergmeister, H., Kollias, G., Steiner, G., Smolen, J. S., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63144-6 · Cited by 134
Role of periodontal ligament fibroblasts in osteoclastogenesis: a review
Sokos, D., Everts, V. E., & de Vries, T. J. (2014) · Journal of Periodontal Research · doi:10.1111/jre.12197 · Cited by 141
Exploring the mechanisms regulating regeneration of deer antlers
Price, J. S., & Allen, S. (2004) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2004.1471 · Cited by 129
RANK ligand as a therapeutic target for bone metastases and multiple myeloma
Roodman, G. D., & Dougall, W. C. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.09.002 · Cited by 127
Saidenberg-Kermanac'h, N., Corrado, A., Lemeiter, D., deVernejoul, M. C., Boissier, M. C., & Cohen-Solal, M. E. (2004) · Bone · doi:10.1016/j.bone.2004.07.004 · Cited by 117
Dunn, M. D., Park, C. H., Kostenuik, P. J., Kapila, S., & Giannobile, W. V. (2007) · Bone · doi:10.1016/j.bone.2007.04.194 · Cited by 109
Nagasawa, T., Kobayashi, H., Kiji, M., Aramaki, M., Mahanonda, R., Kojima, T., MURAKAMI, Y., Saito, M., Morotome, Y., & Ishikawa, I. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.01990.x · Cited by 106
Harrison, B., Silman, A. J., Wiles, N., Scott, D. G. I., & Symmons, D. P. M. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200102)44:2 · Cited by 103
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2005.20.12.2274 · Cited by 99
Self-citationMorony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H. L., Capparelli, C., Starnes, C., Weimann, B., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1583 · Cited by 97
Self-citationMakhluf, H. A., Mueller, S. M., Mizuno, S., & Glowacki, J. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2182 · Cited by 97
Role for osteoprotegerin in rheumatoid inflammation
Saidenberg-Kermanac’h, N., Cohen-Solal, M. E., Bessis, N., de Vernejoul, M. C., & Boissier, M. (2004) · Joint Bone Spine · doi:10.1016/s1297-319x(03)00131-3 · Cited by 93
Ragab, A. A., Nalepka, J. L., Bi, Y.-M., & Greenfield, E. (2002) · American Journal of Physiology - Cell Physiology · doi:10.1152/ajpcell.00421.2001 · Cited by 99
Yamamoto, H., Shevde, N. K., Warrier, A., Plum, L. A., DeLuca, H. F., & Pike, J. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304737200 · Cited by 90
Calcitonin Receptor Plays a Physiological Role to Protect Against Hypercalcemia in Mice
Davey, R. A., Turner, A. G., McManus, J. F., Chiu, W. M., Tjahyono, F., Moore, A. J., Atkins, G. J., Anderson, P. H., Ma, C., Glatt, V., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080310 · Cited by 87
Molecular control of bone remodeling and osteoporosis
Kong, Y., & Penninger, J. M. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00178-9 · Cited by 86
Price, P. A., Caputo, J. M., & Williamson, M. K. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1171 · Cited by 82
The role of the bone microenvironment in skeletal metastasis
Zheng, Y., Zhou, H., Dunstan, C. R., Sutherland, R. L., & Seibel, M. J. (2012) · Journal of bone oncology · doi:10.1016/j.jbo.2012.11.002 · Cited by 87
Self-citationStolina, M., Schett, G. A., Dwyer, D., Vonderfecht, S. L., Middleton, S. C., Duryea, D., Pacheco, E., Van, G. Y., Bolon, B. N., Feige, U., et al. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2879 · Cited by 81
Biology of bone and how it orchestrates the form and function of the skeleton
Sommerfeldt, D. W., & Rubin, C. T. (2002) · Springer eBooks · doi:10.1007/978-3-642-56071-2_2 · Cited by 80
Ma, T., Miyanishi, K., Suen, A., Epstein, N. J., Tomita, T., Smith, R. L., & Goodman, S. (2004) · Cytokine · doi:10.1016/j.cyto.2004.02.001 · Cited by 88
Yoshida, T., & Stern, P. H. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.003 · Cited by 76
Kukreja, A., Radfar, S., Sun, B., Insogna, K. L., & Dhodapkar, M. V. (2009) · Blood · doi:10.1182/blood-2009-03-211920 · Cited by 76
PTH and PTHrP Effects on the Skeleton
Karaplis, A. C., & Goltzman, D. (2000) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1026526703898 · Cited by 76
Human osteoblasts produce cathepsin K
Mandelin, J., Hukkanen, M., Li, T.-F., Korhonen, M. O., Liljeström, M., Sillat, T., Hanemaaijer, R., Salo, J., Santavirta, S. S., & Konttinen, Y. T. (2005) · Bone · doi:10.1016/j.bone.2005.10.017 · Cited by 73
TRAF5 Functions in Both RANKL‐ and TNFα‐Induced Osteoclastogenesis
Kanazawa, K., Azuma, Y., Nakano, H., & Kudo, A. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.3.443 · Cited by 71
Designing proteins for bone targeting
Gittens, S. A., BANSAL, G., Zernicke, R. F., & Uludağ, H. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.015 · Cited by 68
TGF-β1 and IFN-γ Direct Macrophage Activation by TNF-α to Osteoclastic or Cytocidal Phenotype
Fox, S. W., Fuller, K., Bayley, K. E., Lean, J. M., & Chambers, T. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.9.4957 · Cited by 67
Byrne, F. R., Morony, S., Warmington, K., Geng, Z., Brown, H. L., Flores, S. A., Fiorino, M., Yin, S. L., Hill, D., Porkess, V., et al. (2004) · Gut · doi:10.1136/gut.2003.035113 · Cited by 65
Self-citationInhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies
McClung, M. R. (2006) · Current Osteoporosis Reports · doi:10.1007/s11914-006-0012-7 · Cited by 62
Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria.
O'Brien, E. A., Williams, J. H. H., & Marshall, M. J. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3129 · Cited by 61
Mundy, G. R., Oyajobi, B. O., Gutierrez, G. E., Sterling, J. A. R., Padalecki, S. S., Elefteriou, F., & Zhao, M. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50020-3 · Cited by 59
Sabokbar, A., Itonaga, I., Sun, S.-G., Kudo, O., & Athanasou, N. (2005) · Journal of Orthopaedic Research · doi:10.1016/j.orthres.2004.10.006 · Cited by 61
Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis
Bolon, B. N., Shalhoub, V., Kostenuik, P. J., Campagnuolo, G., Morony, S., Boyle, W. J., Zack, D. J., & Feige, U. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10680 · Cited by 57
Self-citationLocal Delivery of Recombinant Osteoprotegerin Enhances Postorthodontic Tooth Stability
Hudson, J. B., Hatch, N. E., Hayami, T., Shin, J. M., Stolina, M., Kostenuik, P. J., & Kapila, S. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9579-4 · Cited by 51
The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: New insights from animal models
Neumann, E., Gay, S., & Müller‐Ladner, U. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21361 · Cited by 45
Increased Levels of Osteoprotegerin in Hemodialysis Patients
Avberšek-Lužnik, I., Malešič, I., Rus, I., & Marc, J. (2002) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2002.177 · Cited by 47
Miller, R. E., Branstetter, D. G., Armstrong, A. P., Kennedy, B., Jones, J. C., Cowan, L. A., Bussiere, J. L., & Dougall, W. C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.1.266 · Cited by 46
Regulatory effects of osteoprotegerin on cellular and humoral immune responses.
Stolina, M., Guo, J., Faggioni, R., Brown, H., & Senaldi, G. (2003) · Clinical Immunology · doi:10.1016/j.clim.2003.09.001 · Cited by 44
RANKL inhibition in the treatment of bone metastases
Lipton, A., & Jun, S. (2008) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e32830baac2 · Cited by 44
Xue, Y., Zhang, Z., Karaplis, A. C., Hendy, G. N., Goltzman, D., & Miao, D. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050608 · Cited by 43
Denosumab for bone diseases: translating bone biology into targeted therapy
Tsourdi, E. A., Rachner, T. D., Rauner, M., Hamann, C., & Hofbauer, L. C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0454 · Cited by 41
Saidenberg-Kermanac’h, N., Bessis, N., Lemeiter, D., de Vernejoul, M. C., Boissier, M., & Cohen-Solal, M. E. (2004) · Journal of Clinical Immunology · doi:10.1023/b:joci.0000029116.12371.bf · Cited by 41
Inhibition of bone resorption and growth of breast cancer in the bone microenvironment
Buijs, J. T., Que, I., Löwik, C. W. G. M., Papapoulos, S. E., & van der Pluijm, G. (2008) · Bone · doi:10.1016/j.bone.2008.10.047 · Cited by 40
Tong, X., Ganta, R. R., & Liu, Z. (2020) · Biology of the Cell · doi:10.1111/boc.202000008 · Cited by 42
The effects of osteoprotegerin on the mechanical properties of rat bone.
Ross, A. B., Bateman, T. A., Kostenuik, P. J., Ferguson, V. L., Lacey, D. L., Dunstan, C. R., & Simske, S. J. (2001) · Journal of Materials Science: Materials in Medicine · doi:10.1023/a:1011229324412 · Cited by 39
Self-citationTurner, A. G., Tjahyono, F., Chiu, W. S. M., Skinner, J., Sawyer, R., Moore, A. J., Morris, H. A., Findlay, D. M., Zajac, J. D., & Davey, R. A. (2011) · Bone · doi:10.1016/j.bone.2010.09.013 · Cited by 39
Funk, J. L. (2001) · International Immunopharmacology · doi:10.1016/s1567-5769(01)00040-6 · Cited by 39
Yamazaki, M., Kawai, M., Miyagawa, K., Ohata, Y., Tachikawa, K., Kinoshita, S., Nishino, J., Ozono, K., & Michigami, T. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0598-2 · Cited by 38
Suppression of polyethylene particle–induced osteolysis by exogenous osteoprotegerin
von Knoch, F., Heckelei, A., Wedemeyer, C., Saxler, G., Hilken, G., Brankamp, J., Sterner, T., Landgraeber, S., Henschke, F., Löer, F., et al. (2005) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.30441 · Cited by 37
Retinal and choroidal neovascularization
Campochiaro, P. A. (2000) · Journal of Cellular Physiology · doi:10.1002/1097-4652(200009)184:3 · Cited by 393
RANKL inhibition for the management of patients with benign metabolic bone disorders
Anastasilakis, A. D., Toulis, K. A., Pοlyzos, S. A., & Terpos, E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903048929 · Cited by 37
Inflammasomes and the IL-1 Family in Bone Homeostasis and Disease
Tseng, H., Samuel, S. G., Schroder, K., Lévesque, J.-P., & Alexander, K. A. (2022) · Current Osteoporosis Reports · doi:10.1007/s11914-022-00729-8 · Cited by 36
Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption
Onyia, J. E., Galvin, R. J. S., Li, Y., Halladay, D., Miles, R. R., Yang, X., Fuson, T. R., Cain, R. L., Zeng, Q. Q., Chandrasekhar, S., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.057893 · Cited by 34
Vitamin D and Osteoclastogenesis
Yasuda, H., Higashio, K., & Suda, T. (2005) · Elsevier eBooks · doi:10.1016/b978-012252687-9/50041-3 · Cited by 35
Terencio, M. C., Ferrándiz, M. L., Carceller, M. C., Ruhí, R., Dalmau, P., Vergés, J., Montell, E., Torrent, A., & Alcaraz, M. J. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.02.005 · Cited by 33
Metadata
- Authors
- Morony, S., Capparelli, C., Lee, R., Shimamoto, G., Boone, T., Lacey, D. L., & Dunstan, C. R.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Dunstan, Colin R.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-09-01
- Volume
- 14
- Issue
- 9
- Pages
- 1478-1485
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2050716165
- Cited by
- 187
- References
- 43
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2022: 2 · 2020: 3 · 2019: 4 · 2017: 3 · 2016: 2 · 2015: 3 · 2014: 3 · 2013: 2 · 2012: 7
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- osteoprotegerin, hypercalcemia, bone resorption, osteoclasts, IL-1β, TNF-α, parathyroid hormone, parathyroid hormone-related protein, 1,25-dihydroxyvitamin D3, hyperparathyroidism, humoral hypercalcemia of malignancy, osteoporosis, inflammatory bone disease, bone metabolism
- MeSH terms
- Animals, Bone and Bones, Bone Resorption, Calcitriol, Calcium, Cell Count, Glycoproteins, Humans, Hypercalcemia, Interleukin-1, Isomerism, Male, Osteoclasts, Parathyroid Hormone, Proteins, Radiography, Tumor Necrosis Factor-alpha, Weight Loss, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Parathyroid Hormone-Related Protein, Mice, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
